Article
Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany.
PharmacoEconomics - 1 Nov 2015
Schremser Katharina, Rogowski Wolf H, Adler-Reichel Sigrid, Tufman Amanda L H, Huber Rudolf M, Stollenwerk Björn
Abstract excerpt
BACKGROUND: Lung cancer is among the top causes of cancer-related deaths. Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors can increase progression-free survival compared with standard chemotherapy in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). OBJECTIVE: The aim of the study was to evaluate the cost-effectiveness of EGFR mutation analysis and first-line...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.